Urinary Tract Infection Market Size

Global Urinary Tract Infection Market Overview

The urinary tract infection market size was valued at USD 10.6 billion in 2023 and is projected to grow from USD 10.8 Billion in 2024 to USD 16.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2% during the forecast period (2023 - 2032). The UTI testing market is witnessing growth owing to factors such as increasing disease burden, rapid technological advancements, increasing geriatric population, and R&D investments by key players to introduce self-test products. These are just a few of the market drivers that are driving the market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Growth in the urinary tract infection (UTI) testing market is being driven by factors such as the rising prevalence of UTIs, the proliferation of cutting-edge diagnostic tools, the aging of the global population, and the efforts of major industry players to develop and distribute at-home test kits. These are only a handful of the factors that are pushing the industry forward. The industry is also anticipated to benefit from the introduction of more effective combination medications and the rising elderly population.

UTIs affect women at a higher rate than men. The incidence rate rises as women get older. Due to changes in vaginal flora that promote the growth of some pathogens, the infection rate is higher in postmenopausal women. The availability of home sample collection kits and self-test kits for UTI testing, as well as the introduction of portable hand-held devices, are all likely to increase uptake.

People with diabetes are more likely to develop urinary tract infections because sugar in the urine provides a fertile environment for bacteria. The global urinary tract infection therapeutics market is being driven by the rising incidence of diabetes and kidney stones, both of which enhance the likelihood of developing a urinary tract infection (UTI).

Market expansion is being stymied, however, by such factors as medication-related side effects and a general lack of knowledge about the frequency of UTIs in less developed regions of the world.

Spero Therapeutics Inc. submitted Tebipenem HBr tablets in cUTI, including pyelonephritis caused by susceptible microorganisms, to the US FDA in October 2021.

Indian generics major BDR Pharma brought Biapenem into the market in September 2021. It is used for complicated urinary tract infections as well as lower respiratory and intra-abdominal infections.

Sysmex Corporation introduced a fully automated instrument called ‘UF-1500,’ a urine sediment testing device in September 2022. Furthermore, Vela Diagnostics and PathoKey MP UTI ID developed the AMR PCR Test and used it to diagnose UTI Pathogens and Antimicrobial Resistance Genes.

In October 2021, the company Spero Therapeutics Inc. submitted a new drug application to the United States Food and Drug Administration for Tebipenem HBr tablets indicated for treating complicated urinary infections (cUTIs), including pyelonephritis, caused by bacteria that can be killed by this antibiotic.

August 2023: An inexpensive gadget for detecting the specific bacterium that causes urinary tract infections (UTIs) has been developed by researchers at the Indian Institute of Technology (IIT) Guwahati using a 3D printer. According to the institute's announcement, it is a "fast, accurate, and reliable device" that can measure and identify the type of bacteria in a patient suspected of having a UTI. The institute claimed it was economical and could be used even in rural regions, where a lack of testing facilities causes the majority of UTI cases to go undiagnosed. Comparatively, other diagnostic devices employ urine culture, which can take a few days, but this one can measure and identify the type of bacteria in a UTI suspect patient in just 5 minutes.

Urinary Tract Infection Market Trends

• Rising Use of Urinary Catheters and Other Drainage Devices to propel market growth

With the rising incidence of chronic kidney diseases such as bladder cancer and renal failure, Patients use catheters and other drainage devices. Easier access to patients with urinary catheters and Complicated urinary tract infections. According to the World Health Organization (WHO), the risk of bacteriuria is approximately 5% per day. Of patients using urinary catheters, 40% had nosocomial infections. Certain factors include prolonged catheterization duration, lack of systemic antibiotic therapy, bacterial Colonization in the drainage bag, rapid fata underlying disease, etc. May lead to catheter-related urinary tract infections. Therefore, increased use of urinary catheters promotes the growth of the urinary tract Infection Treatment Market.

Women are more prone to UTIs than men. Incidence in adult females increases with age. Infection rates are higher in postmenopausal women because of changes in the vaginal flora that provide a favorable environment for the growth of certain pathogens.

Introduction of portable hand-held devices and availability of home sample collection kits and self-test kits for UTI testing are among the factors likely to boost adoption. For example, in May 2020, Healthy.io Ltd. launched a home testing kit in the UK. Moreover, point-of-care detection of UTIs will be a key growth area, which is expected to increase investments by companies. In addition, researchers are developing technologically advanced disease diagnostic products that are expected to be commercialized in space in the next few years. In January 2020, engineers at the University of Bath developed the UTI test using smartphone cameras. They claim it can detect the presence of E. coli in a urine sample in less than 25 minutes. Thus, this factor is driving the market CAGR. Thus, it is anticipated that this aspect will accelerate Urinary Tract Infection market revenue globally.

Urinary Tract Infection Market Segment Insights

Urinary Tract Infection Drug Class Insights

Based on Drug Class, the market segments of urinary tract infection includes quinolones, beta & cephalosporins, aminoglycosides, penicillin and azoles. The quinolones segment held the majority share in 2022 in the Urinary Tract Infection market data. Many doctors advise their patients to take quinolones promptly to clear up the infection. Moreover, the quinolones industry is expected to grow at the fastest CAGR during the forecast period.

Figure 2: Urinary Tract Infection Market, by Drug Class, 2022 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Urinary Tract Infection Application Insights

Based on application, the Urinary Tract Infection market segmentation includes urethritis, cystitis and pyelonephritis. The cystitis segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2030. This can be attributed to the high incidence and recurrence rate of cystitis, the increasing number of product approvals, and the high number of diabetic patients more prone to cystitis. Globally, approximately 10 in 100 women develop acute cystitis each year, according to the NCBI's Epidemiology Report. Also, its recurrence rate is higher in women; half of those with cystitis will get cystitis again within a year.

Urinary Tract Infection Pathogen Insights

The market segmentation of Urinary Tract Infection, based on the pathogen, includes escherichia coli, staphylococcus saprophyticus, klebsiella pneumoniae, proteus mirabilis and enterococcus faecalis. The Escherichia coil segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2030. Healthcare providers are encouraging the increased incidence of community-acquired urinary tract infections caused by the Escherichia coli (E. Coil) pathogen due to the presence of antibiotics in patients. Therefore, stakeholders in the urinary tract infection treatment market must meet the growing demand for effective antibiotic drugs for UTIs caused by Escherichia coli pathogens.

Urinary Tract Infection End User Insights

The market data of Urinary Tract Infection, based on end users, includes hospitals, clinics and self-administered. The hospital segment dominated the market revenue of Urinary Tract Infection  in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. This is due to an increase in cases of hospital-acquired urinary tract infections. However, the diagnostic laboratories segment is projected to register the highest CAGR in 2031. Laboratory diagnosis is based on cultured colony counts, which reflect the concentration of organisms in the urine.

May 2023: A prototype diagnostic sensor developed by UT Southwestern Medical Center researchers may one day allow people to confirm the presence of urinary tract infections (UTIs) without waiting for laboratory test results (which can take anywhere from 24 to 48 hours). Up to 85% accuracy in detecting a UTI is presently achieved by using the new method, which involves the detection and determination of the concentration of three protein biomarkers in urine. According to the study's authors, this approach has the potential to increase the diagnostic accuracy of existing electrochemical biosensors, leading to more targeted treatment and better health outcomes for patients. 

Urinary Tract Infection Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Urinary Tract Infection market accounted for USD 3.9 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The region is experiencing a dramatic increase in innovations related to diagnostic methods for UTIs. During a routine UTI examination, a woman was observed to be infected with E. coli that showed resistance to last-resort antibiotics, according to a November 2020 paper by Pranita D. Tamma in Infectious Diseases Society of America, colistin.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. 

Figure 3: URINARY TRACT INFECTION MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Urinary Tract Infection market accounts for the second-largest market share. Factors such as an increase in the geriatric population, research & development programs, and high-class healthcare infrastructure are boosting demand in Germany's urinary cystitis management market. Moreover, the U.K. market of urinary tract infection held the largest market share, and the Germany market of urinary tract infection was the fastest-growing market in the region.

Asia Pacific Urinary Tract Infection Market is expected to grow at the fastest CAGR from 2022 to 2030. The high growth rate can be attributed to rising disease incidence and the aging population. Increasing demand for cost-effective diagnostics and a growing population are important factors driving the market growth. Asia-Pacific markets such as Australia and South Korea already have a medical reimbursement system that covers UTI diagnostic testing. Further, the China market of urinary tract infection held the largest market share, and the India market of urinary tract infection was the fastest-growing market in the region.

Urinary Tract Infection Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of urinary tract infection even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Urinary Tract Infection industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies manufacturers adopt in the Urinary Tract Infection industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, Urinary Tract Infection industry has provided medicine with some of the most significant benefits. The Urinary Tract Infection markets major players such as Nestle, JM Smucker Company, The Kraft Heinz Company and Starbucks Urinary Tract Infection Company.

Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's business areas include pharmaceuticals, consumer healthcare, agrochemicals, seeds and biotechnology products. In August 2021, the company announced the acquisition of division therapeutics, a US-headquartered biopharmaceutical company using novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics.

Also, Merck & Co. was originally established in 1891 as the U.S. subsidiary of the Merck Group. Merck develops and manufactures pharmaceuticals, vaccines, biotherapeutics and animal health products. It has several blockbuster drugs or products, each generating revenue in 2020, including cancer immunotherapies, anti-diabetic drugs, and vaccines against HPV and chickenpox. In February 2023, Merck announced that the Phase 3 NRG-GY018 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with standard-of-care chemotherapy (carboplatin and paclitaxel), met its primary endpoint of progression-free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.

Key Companies in the Urinary Tract Infection market include

• Pfizer Inc.


• Teva Pharmaceuticals


• Novo Nordisk A/S


• GlaxoSmithKline plc


• Bayer AG


• Novartis Ag


• Cipla Inc.


• Merck & Co. Inc.


• Eli Lily Company


• Allergan

Urinary Tract Infection Industry Developments

October 2021:Spero Therapeutics Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for imipenem hydrobromide tablets for the treatment of complicated urinary tract infections (cUTI ), including those caused by pyelonephritis. Susceptible microorganisms.

September 2021:BDR Pharma, one of India's leading generic pharmaceutical companies, launched biapenem to treat patients with intra-abdominal infection, lower respiratory tract infection or complicated urinary tract infection.

Urinary Tract Infection Market Segmentation

Urinary Tract Infection Drug Class Outlook (USD Billion, 2019-2030)

• Quinolones


• Beta & Cephalosporins


• Aminoglycosides


• Penicillin


• Azoles

Urinary Tract Infection Application Outlook (USD Billion, 2019-2030)

• Urethritis


• Cystitis


• Pyelonephritis

Urinary Tract Infection Pathogen Outlook (USD Billion, 2019-2030)

• Escherichia coli


• Staphylococcus saprophyticus


• Klebsiella pneumoniae


• Proteus mirabilis


• Enterococcus faecalis

Urinary Tract Infection End-User Outlook (USD Billion, 2019-2030)

• Hospitals


• Clinics


• Self-Administered

Urinary Tract Infection Regional Outlook (USD Billion, 2019-2030)

• North America


• US


• Canada


• Europe


• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America